Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of EP-9001A for moderate to severe bone metastasis cancer pain
CTR20231998Phase 2Active
- Sponsor
- Youluo Biotech
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of EP-9001A in bone metastases, cancer pain, sponsored by Youluo Biotech. Started Nov 2023; status: active.
02
Drugs
EP-9001A
03
Conditions
bone metastasescancer pain
Beyond the preview
Go deeper on CTR20231998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231998.